Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

Timothy P. Hughes, Giuseppe Saglio, Hagop M. Kantarjian, François Guilhot, Dietger Niederwieser, Gianantonio Rosti, Chiaki Nakaseko, Carmino Antonio De Souza, Matt E. Kalaycio, Stephan Meier, Xiaolin Fan, Hans D. Menssen, Richard A. Larson, Andreas Hochhaus

Blood (2014) 123 (9): 1353–1360.

https://doi.org/10.1182/blood-2013-06-510396

Published: 2014

Includes: Supplemental data

Journal Articles

ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes

Giuseppe Saglio, Andreas Hochhaus, MD, Timothy P. Hughes, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Hirohisa Nakamae, MD, PhD, Dong-Wook Kim, MD, PhD, Saengsuree Jootar, Gabriel Etienne, MD, PHD, Ian Flinn, MD, PhD, Jeffrey H. Lipton, MD, PhD, Ricardo Pasquini, MD, PhD, Beatriz Moiraghi, MD, Charisse Kemp, Xiaolin Fan, PhD, Hans D. Menssen, MD, PhD, Hagop M. Kantarjian, MD, Richard A. Larson, MD

Blood (2013) 122 (21): 92.

https://doi.org/10.1182/blood.V122.21.92.92

Published: 2013

Journal Articles

Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase

Andreas Hochhaus, Giuseppe Saglio, Richard A. Larson, Dong-Wook Kim, Gabriel Etienne, Gianantonio Rosti, Carmino De Souza, Mineo Kurokawa, Matt E. Kalaycio, Albert Hoenekopp, Xiaolin Fan, Yaping Shou, Hagop M. Kantarjian, Timothy P. Hughes

Blood (2013) 121 (18): 3703–3708.

https://doi.org/10.1182/blood-2012-04-423418

Published: 2013

Journal Articles

Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients)

Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, Giuseppe Saglio, François Guilhot, Haifa Kathrin Al-Ali, MD, Giantonio Rosti, Chiaki Nakaseko, MD, PhD, Carmino Antonio De Souza, PhD, Charisse Kemp, Xiaolin Fan, PhD, Albert Hoenekopp, MD, Richard A. Larson, MD, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 167.

https://doi.org/10.1182/blood.V120.21.167.167

Published: 2012

Journal Articles

Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Hagop M. Kantarjian, MD, Dong-Wook Kim, MD, Surapol Issaragrisil, MD, Richard E Clark, Josy Reiffers, MD, Franck E. Nicolini, MD, PhD, Ricardo Pasquini, Matt Kalaycio, MD, Timothy P. Hughes, MD, MBBS, Andreas Hochhaus, MD, Charisse Kemp, Xiaolin Fan, PhD, Roger J. Waltzman, MD, Giuseppe Saglio, MD, Richard A. Larson, MD

Blood (2012) 120 (21): 1676.

https://doi.org/10.1182/blood.V120.21.1676.1676

Published: 2012

Journal Articles

Assessment of Patient Reported Outcomes (PROs) From the Enestnd Trial with Minimum Follow-up of 36 Cycles.

Jennifer L Beaumont, MS, Matthew Magestro, John Coombs, PharmD, MBA, Xiaolin Fan, PhD, Charisse Kemp, Roger J. Waltzman, MD

Blood (2012) 120 (21): 3166.

https://doi.org/10.1182/blood.V120.21.3166.3166

Published: 2012

Journal Articles

Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,

Blood (2011) 118 (21): 3770.

https://doi.org/10.1182/blood.V118.21.3770.3770

Published: 2011

NARROW

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes

Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase

Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients)

Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Assessment of Patient Reported Outcomes (PROs) From the Enestnd Trial with Minimum Follow-up of 36 Cycles.

Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,

Email alerts

ASH Publications

American Society of Hematology

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes

Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase

Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients)

Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Assessment of Patient Reported Outcomes (PROs) From the Enestnd Trial with Minimum Follow-up of 36 Cycles.

Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only